IL292693B1 - Mrgprx2 antagonists and their uses - Google Patents
Mrgprx2 antagonists and their usesInfo
- Publication number
- IL292693B1 IL292693B1 IL292693A IL29269322A IL292693B1 IL 292693 B1 IL292693 B1 IL 292693B1 IL 292693 A IL292693 A IL 292693A IL 29269322 A IL29269322 A IL 29269322A IL 292693 B1 IL292693 B1 IL 292693B1
- Authority
- IL
- Israel
- Prior art keywords
- compound
- alkyl
- optionally substituted
- composition
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962931186P | 2019-11-05 | 2019-11-05 | |
| US201962931576P | 2019-11-06 | 2019-11-06 | |
| US202063046481P | 2020-06-30 | 2020-06-30 | |
| PCT/US2020/059228 WO2021092264A1 (en) | 2019-11-05 | 2020-11-05 | MrgprX2 ANTAGONISTS AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL292693A IL292693A (en) | 2022-07-01 |
| IL292693B1 true IL292693B1 (en) | 2026-05-01 |
Family
ID=73740488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292693A IL292693B1 (en) | 2019-11-05 | 2020-11-05 | Mrgprx2 antagonists and their uses |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230002336A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4055011A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7787811B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114728919B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020380926B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3159633A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292693B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021092264A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115850094B (zh) * | 2022-09-07 | 2025-02-11 | 北华航天工业学院 | 一种利用1,2-环氧丁烷合成β-氨基醇的方法 |
| WO2025002360A1 (zh) * | 2023-06-30 | 2025-01-02 | 北京普祺医药科技股份有限公司 | 一种mrgprx2拮抗剂、药物组合物以及其用途 |
| US20250084063A1 (en) | 2023-08-18 | 2025-03-13 | Incyte Corporation | Bicyclic heterocycles as mrgprx2 antagonists |
| WO2025160430A1 (en) | 2024-01-25 | 2025-07-31 | Incyte Corporation | Bicyclic heterocycles as mrgprx2 antagonists |
| WO2025163462A1 (ko) * | 2024-02-02 | 2025-08-07 | 삼진제약주식회사 | 헤테로고리를 갖는 mrgprx2((mas-related g-protein coupled receptor member x2) 길항제 유도체와 이의 용도 |
| WO2025222076A1 (en) | 2024-04-19 | 2025-10-23 | Kyorin Pharmaceutical Co., Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as mrgprx2 antagonists for the treatment of inflammatory diseases |
| WO2025222040A1 (en) | 2024-04-19 | 2025-10-23 | Escient Pharmaceuticals, Inc. | Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige |
| US12630562B2 (en) | 2024-08-07 | 2026-05-19 | Arcus Biosciences, Inc. | Piperidylurea compounds and methods of use thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4158659A (en) * | 1975-06-05 | 1979-06-19 | Lilly Industries Limited | Acylamino derivatives |
| WO2004089415A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
| US20090163545A1 (en) * | 2007-12-21 | 2009-06-25 | University Of Rochester | Method For Altering The Lifespan Of Eukaryotic Organisms |
| WO2015089327A1 (en) * | 2013-12-11 | 2015-06-18 | Biogen Idec Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| US20160096834A1 (en) * | 2014-10-06 | 2016-04-07 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| EP0084665B1 (de) * | 1982-01-22 | 1986-08-13 | BASF Aktiengesellschaft | Thiadiazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| GB0308511D0 (en) * | 2003-04-14 | 2003-05-21 | Astex Technology Ltd | Pharmaceutical compounds |
| BRPI0413709A (pt) * | 2003-08-21 | 2006-10-17 | Pfizer Prod Inc | compostos para o tratamento de distúrbios neurodegenerativos |
| DE102004009933A1 (de) * | 2004-02-26 | 2005-09-15 | Merck Patent Gmbh | Verwendung von Thiadiazolharnstoffderivaten |
| EP2125799A1 (en) | 2007-02-28 | 2009-12-02 | Smithkline Beecham Corporation | Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase |
| EP2725022B1 (de) * | 2008-06-13 | 2017-03-29 | Bayer CropScience AG | Neue Amide als Schädlingsbekämpfungsmittel |
| WO2010073011A2 (en) * | 2008-12-23 | 2010-07-01 | Betagenon Ab | Compounds useful as medicaments |
| US8377639B2 (en) * | 2009-06-26 | 2013-02-19 | University Of Massachusetts | Compounds for modulating RNA binding proteins and uses therefor |
| RU2601550C2 (ru) * | 2010-12-09 | 2016-11-10 | Вокхардт Лимитед | Кетолидные соединения |
| JP6130383B2 (ja) * | 2011-09-30 | 2017-05-17 | エンドゥ ファーマシューティカルズ,インコーポレイティド | ピリジン誘導体 |
| CN104955332B (zh) * | 2013-01-30 | 2017-03-29 | 住友化学株式会社 | 防治节足害虫的方法 |
| BR112019018230A2 (pt) * | 2017-03-02 | 2020-07-21 | Assembly Biosciences, Inc. | compostos de sulfamida cíclica e métodos de sua utilização |
-
2020
- 2020-11-05 AU AU2020380926A patent/AU2020380926B2/en active Active
- 2020-11-05 JP JP2022526331A patent/JP7787811B2/ja active Active
- 2020-11-05 WO PCT/US2020/059228 patent/WO2021092264A1/en not_active Ceased
- 2020-11-05 IL IL292693A patent/IL292693B1/en unknown
- 2020-11-05 US US17/773,414 patent/US20230002336A1/en active Pending
- 2020-11-05 EP EP20820596.3A patent/EP4055011A1/en active Pending
- 2020-11-05 CN CN202080082802.5A patent/CN114728919B/zh active Active
- 2020-11-05 CA CA3159633A patent/CA3159633A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4158659A (en) * | 1975-06-05 | 1979-06-19 | Lilly Industries Limited | Acylamino derivatives |
| WO2004089415A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
| US20090163545A1 (en) * | 2007-12-21 | 2009-06-25 | University Of Rochester | Method For Altering The Lifespan Of Eukaryotic Organisms |
| WO2015089327A1 (en) * | 2013-12-11 | 2015-06-18 | Biogen Idec Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| US20160096834A1 (en) * | 2014-10-06 | 2016-04-07 | Merck Patent Gmbh | Heteroaryl compounds as btk inhibitors and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114728919B (zh) | 2025-12-30 |
| AU2020380926B2 (en) | 2026-07-16 |
| AU2020380926A1 (en) | 2022-05-26 |
| CA3159633A1 (en) | 2021-05-14 |
| WO2021092264A1 (en) | 2021-05-14 |
| IL292693A (en) | 2022-07-01 |
| JP2022554392A (ja) | 2022-12-28 |
| CN114728919A (zh) | 2022-07-08 |
| US20230002336A1 (en) | 2023-01-05 |
| EP4055011A1 (en) | 2022-09-14 |
| JP7787811B2 (ja) | 2025-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292692B1 (en) | Mrgprx2 antagonists and their uses | |
| IL291244A (en) | hpk1 antagonists and uses thereof | |
| IL294052B2 (en) | Fluoroalkyl oxadiazoles and their uses | |
| IL275463A (en) | TLR7/8 antagonists and their use | |
| IL285177A (en) | compounds and their use | |
| GB201905552D0 (en) | Antagonists | |
| IL286497A (en) | compounds and their use | |
| IL277502A (en) | Compounds and uses for them | |
| SG11202100818RA (en) | Tlr7/8 antagonists and uses thereof | |
| IL280808A (en) | OX40-binding polypeptides and their uses | |
| GB2603645B (en) | Polypeptides having anti-senescent effects and uses thereof | |
| IL292693A (en) | Mrgprx2 antagonists and uses thereof | |
| IL287782A (en) | Cd33-binding polypeptides and uses thereof | |
| SG11202103021VA (en) | Cd40l antagonist and uses thereof | |
| IL274751A (en) | ILDR2 antagonists and combinations thereof | |
| ZA202101406B (en) | Integrin antagonists | |
| IL291499A (en) | Azaquinoline compounds and their uses | |
| GB201815629D0 (en) | Antagonists | |
| IL269836B (en) | Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use | |
| IL287503A (en) | Thio-semicarbazide compounds and their use | |
| IL284764A (en) | compounds and their uses | |
| IL279483A (en) | Cyanotriazole compounds and their uses | |
| GB201819200D0 (en) | Polypeptide and uses thereof | |
| IL288828A (en) | Binding factors - cd38 and their use | |
| IL313687A (en) | OXER1 antagonists and their uses |